<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35057809</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.</ArticleTitle><Pagination><StartPage>19</StartPage><MedlinePgn>19</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-021-02339-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Comprehensive data on the cerebrospinal fluid (CSF) profile in patients with COVID-19 and neurological involvement from large-scale multicenter studies are missing so far.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze systematically the CSF profile in COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centers RESULTS: The most frequent pathological finding was blood-CSF barrier (BCB) dysfunction (median QAlb 11.4 [6.72-50.8]), which was present in 58/116 (50%) samples from patients without pre-/coexisting CNS diseases (group I). QAlb remained elevated&#x2009;&gt;&#x2009;14d (47.6%) and even&#x2009;&gt;&#x2009;30d (55.6%) after neurological onset. CSF total protein was elevated in 54/118 (45.8%) samples (median 65.35&#xa0;mg/dl [45.3-240.4]) and strongly correlated with QAlb. The CSF white cell count (WCC) was increased in 14/128 (11%) samples&#xa0;(mostly lympho-monocytic; median 10&#xa0;cells/&#xb5;l,&#x2009;&gt;&#x2009;100 in only 4). An albuminocytological dissociation (ACD) was found in 43/115 (37.4%)&#xa0;samples. CSF L-lactate was increased in 26/109 (24%; median 3.04&#xa0;mmol/l [2.2-4]). CSF-IgG was elevated in 50/100 (50%), but was of peripheral origin, since QIgG was normal in almost all cases, as were QIgA and QIgM. In 58/103 samples (56%) pattern 4 oligoclonal bands (OCB) compatible with systemic inflammation were present, while CSF-restricted OCB were found in only 2/103 (1.9%). SARS-CoV-2-CSF-PCR was negative in 76/76 samples. Routine CSF findings were normal in 35%. Cytokine levels were frequently elevated in the CSF (often associated with BCB dysfunction) and serum, partly remaining positive at high levels for weeks/months (939 tests). Of note, a positive SARS-CoV-2-IgG-antibody index (AI) was found in 2/19 (10.5%) patients which was associated with unusually high WCC in both of them and a strongly increased interleukin-6 (IL-6) index in one (not tested in the other). Anti-neuronal/anti-glial autoantibodies were mostly absent in the CSF and serum (1509 tests). In samples from patients with pre-/coexisting CNS disorders (group II [N&#x2009;=&#x2009;19]; including multiple sclerosis, JC-virus-associated immune reconstitution inflammatory syndrome, HSV/VZV encephalitis/meningitis, CNS lymphoma, anti-Yo syndrome, subarachnoid hemorrhage), CSF findings were mostly representative of the respective disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The CSF profile in COVID-19 with neurological symptoms is mainly characterized by BCB disruption in the absence of intrathecal inflammation, compatible with cerebrospinal endotheliopathy. Persistent BCB dysfunction and elevated cytokine levels may contribute to both acute symptoms and 'long COVID'. Direct infection of the CNS with SARS-CoV-2, if occurring at all, seems to be rare. Broad differential diagnostic considerations are recommended to avoid misinterpretation of treatable coexisting neurological disorders as complications of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jarius</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pache</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rtvelyessy</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) in Magdeburg, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jel&#x10d;i&#x107;</LastName><ForeName>Ilijas</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stettner</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franciotta</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurocritical Care Unit, Department of Neurosurgery and Institute of Intensive Care, University Hospital and University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, DONAUISAR Klinikum Deggendorf, Deggendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringelstein</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Faculty, Heinrich-Heine-University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich-Heine-University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senel</LastName><ForeName>Makbule</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regeniter</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medica Medical Laboratories Dr. F. Kaeppeli AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalantzis</LastName><ForeName>Rea</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willms</LastName><ForeName>Jan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Institute of Intensive Care Medicine, University Hospital and University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berthele</LastName><ForeName>Achim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capobianco</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital S. Luigi - Orbassano (I), Orbassano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisele</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichen</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dersch</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinic of Neurology and Neurophysiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic of Neurology and Neurophysiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandner</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayzenberg</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Catharina C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University and University Hospital M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegen</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalil</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleiter</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenhard</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuroinfectiology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aktas</LastName><ForeName>Orhan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Faculty, Heinrich-Heine-University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angstwurm</LastName><ForeName>Klemens</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinschnitz</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewerenz</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumani</LastName><ForeName>Hayrettin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Specialty Hospital of Neurology Dietenbronn, Schwendi, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Friedemann</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Stangel</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ruprecht</LastName><ForeName>Klemens</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wildemann</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>in cooperation with the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1499 TG93 U1</GrantID><Agency>Ministry for Education and Research Baden-W&#xfc;rttemberg, Germany</Agency><Country/></Grant><Grant><GrantID>4078P0_198345</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002556">Cerebrospinal Fluid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043025">Oligoclonal Bands</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002556" MajorTopicYN="N">Cerebrospinal Fluid Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043025" MajorTopicYN="N">Oligoclonal Bands</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013129" MajorTopicYN="N">Spinal Puncture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody index</Keyword><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Blood-CSF barrier</Keyword><Keyword MajorTopicYN="N">Central nervous system</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid (CSF)</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Encephalitis</Keyword><Keyword MajorTopicYN="N">Encephalopathy</Keyword><Keyword MajorTopicYN="N">Guillain&#x2013;Barr&#xe9; syndrome</Keyword><Keyword MajorTopicYN="N">Lumbar puncture</Keyword><Keyword MajorTopicYN="N">Neurological symptoms</Keyword><Keyword MajorTopicYN="N">Oligoclonal bands</Keyword><Keyword MajorTopicYN="N">Polymerase Chain reaction (PCR)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 antibodies</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)</Keyword></KeywordList><CoiStatement>S.J. has nothing to disclose. Fl.P. has nothing to disclose. P.K. has nothing to disclose. I.J. has received speaker honoraria or unrestricted grants from Biogen Idec and Novartis and has served as advisor for Alexion, Neuway, Merck, Novartis and Sanofi Genzyme; none of these are related to this study. M.Ste. served on the scientific advisory boards and/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec; Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer; none related to this study. D.F. has nothing to disclose. E.K. received grants from the Swiss National Science Foundation, Swiss Innovation Promotion Agency (CTI, Innosuisse), European Commission (Eurostars), Velux, von Tobel and USZ foundations; she is member of the advisory boards of Zoll Medical, Bard Medical, Portola. B.N. has nothing to disclose. M.R. received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, and Merck, none related to this study. M.Se. has nothing to disclose. A.R. has nothing to disclose. J.F.W. has nothing to disclose. A.B. has nothing to disclose. M.B. has nothing to disclose. M.C. received personal fees for speaking honoraria and advisory board participation by Biogen, Merck, Novartis, Sanofi, Roche. A.E. has nothing to disclose. I.R. has nothing to disclose. R.D. received lecture fees from Roche and travel grants from Biogen, none related to this study. S.R. reports receiving consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen, Celgene, Merck Serono, Novartis, Sanofi-Aventis, Genzyme, Roche and Teva, none related to this study; furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH Freiburg. K.S. has nothing to disclose. I.A. received travel grants from Biogen Idec and Guthy-Jackson Charitable Foundation, speaker honoraria from Alexion, Merck, Roche and Santhera, served on scientific advisory boards for Roche and Alexion and received research support from Diamed, none related to this manuscript. C.C.G. received speaker honoraria from Mylan, Bayer Healthcare, and Sanofi-Genzyme and travel/accommodation/meeting expenses from Bayer Healthcare, Biogen, EUROIMMUN, Novartis, and Sanofi-Genzyme; she also received research support from Biogen, Novartis, and Roche; none related to the current study. H.H. has participated in meetings&#xa0;sponsored by, received speaker honoraria or travel funding from Bayer, Biogen,&#xa0;Merck,&#xa0;Novartis, Roche, Sanofi-Genzyme, Siemens and Teva, and received&#xa0;honoraria for consulting from Biogen, Novartis and Teva. M.K. has received speaker honoraria from Bayer, Novartis, Merck, Biogen Idec and Teva Pharmaceutical Industries Ltd. and serves on scientific advisory boards for Biogen Idec, Merck Serono, Roche, Novartis, Bristol-Myers Squibb and Gilead. He received research grants from Teva Pharmaceutical Industries, Ltd., Biogen and Novartis. I.K. has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Celgene, chugai, QVIA,Merck, Mylan, Novartis, Roche, Sanofi; none related to this study. T.L. received lecture fees from Pfizer Deutschland GmbH; he received research grants from Baxter Deutschland GmbH and from Stiftung Hospital zum Heiligen Geist Frankfurt, Germany; none related to this study. J.H. has nothing to disclose. O.A. has nothing to disclose. K.A. reports conflicts of interest not related to this paper, including speaker fees from BiogenIdec and travel grants before 2015 from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis and Teva; his institution has been reimbursed for his role as a principal investigator in trials in Neuroimmunology for Alexion, Bayer, BiogenIdec, MerckSerono, Novartis and Roche. C.K. has nothing to disclose. J.L. received funding for COVID-19 research from the Ministry for Education&#xa0;and Research&#xa0;Baden-W&#xfc;rttemberg (1499 TG93 U1); non-related to this paper, he received speaker fees or travel compensation from UCB, Bayer, Roche, Teva and the Cure Huntington&#x2019;s Disease Initiative (CHDI); his institution has been reimbursed for his role as a principal investigator in trials for UCB and CHDI; his research is funded by the European Huntington&#x2019;s Disease Initiative and&#xa0;the German Federal Ministry of Education and Research (BMBF). H.T. reports conflicts of interest not related to this publication including funding for research projects, lectures and travel from Alexion, Bayer, Biogen, Celgene, Genzyme, Fresenius, Merck, Mylan, Novartis, Roche, Siemens Health Diagnostics, and Teva, and received research support from DMSG and German Federal Ministry of Education and Research (BMBF). Fr.P. has nothing to disclose. M.Sta. has nothing to disclose. K.R. received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charit&#xe9; (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria from Bayer and travel grants from Guthy Jackson Charitable Foundation; none of these are related to this study. B.W. received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation and Klaus Tschira Foundation, grants and personal fees from Merck Serono, Sanofi Genzyme, Novartis pharmaceuticals, and personal fees from Alexion, Bayer, Biogen, Teva; none related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35057809</ArticleId><ArticleId IdType="pmc">PMC8771621</ArticleId><ArticleId IdType="doi">10.1186/s12974-021-02339-0</ArticleId><ArticleId IdType="pii">10.1186/s12974-021-02339-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. J Neurol. 2020;267:1573&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238392</ArticleId><ArticleId IdType="pubmed">32436101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR, Schweitzer F, Warnke C. A systematic review of neurological symptoms and complications of COVID-19. J Neurol. 2021;268:392&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370630</ArticleId><ArticleId IdType="pubmed">32691236</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs V, Kutza M, Wischnewski S, Deigendesch N, Lutz L, Kulsvehagen L, Ricken G, Kappos L, Tzankov A, Hametner S, et al. Presence of SARS-CoV-2 transcripts in the choroid plexus of ms and non-ms patients with COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8:e957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862096</ArticleId><ArticleId IdType="pubmed">33504636</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brunink S, Greuel S, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai Y, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, Kotanidou A, Dalakas MC. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020;7:e893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577546</ArticleId><ArticleId IdType="pubmed">32978291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodro M, Compta Y, Llanso L, Esteller D, Doncel-Moriano A, Mesa A, Rodriguez A, Sarto J, Martinez-Hernandez E, Vlagea A, et al. Increased CSF levels of IL-1beta, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357418</ArticleId><ArticleId IdType="pubmed">32611761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon M, Kataria S, Patel J, Mehta TR, Daimee M, Patel V, Prasad A, Chowdhary AA, Jaiswal S, Sriwastava S. A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19. Int J Infect Dis. 2021;104:390&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837002</ArticleId><ArticleId IdType="pubmed">33434662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma RL, Guedes BF, Carra R, Iepsen B, Rodrigues J, Camelo-Filho AE, Kubota G, Ferrari M, Studart-Neto A, Oku MH, et al. Clinical, cerebrospinal fluid, and neuroimaging findings in COVID-19 encephalopathy: a case series. Neurol Sci. 2021;42:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787933</ArticleId><ArticleId IdType="pubmed">33409828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, Melmed KR. Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. 2021;421:117316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833669</ArticleId><ArticleId IdType="pubmed">33561753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lersy F, Benotmane I, Helms J, Collange O, Schenck M, Brisset JC, Chammas A, Willaume T, Lefebvre N, Solis M, et al. Cerebrospinal fluid features in patients with coronavirus disease 2019 and neurological manifestations: correlation with brain magnetic resonance imaging findings in 58 patients. J Infect Dis. 2021;223:600&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798956</ArticleId><ArticleId IdType="pubmed">33249438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M, Rommer PS, Ayzenberg I, Ruprecht K, Klotz L, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020;17:261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470615</ArticleId><ArticleId IdType="pubmed">32883348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Lechner C, Wendel EM, Baumann M, Breu M, Schimmel M, Karenfort M, Marina AD, Merkenschlager A, Thiels C, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. J Neuroinflammation. 2020;17:262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470445</ArticleId><ArticleId IdType="pubmed">32883358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550068</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Konig FB, Metz I, Ruprecht K, Paul F, Bruck W, Wildemann B. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation. 2017;14:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576197</ArticleId><ArticleId IdType="pubmed">28851393</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Wurthwein C, Behrens JR, Wanner J, Haas J, Paul F, Wildemann B. Balo's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. J Neuroinflammation. 2018;15:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774135</ArticleId><ArticleId IdType="pubmed">29347989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Haas J, Paul F, Wildemann B. Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. J Neuroinflammation. 2019;16:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396538</ArticleId><ArticleId IdType="pubmed">30819213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumani H, Petereit H-F: Leitlinie Lumbalpunktion und Liquordiagnostik, S1-Leitlinie, 2019, in: Deutsche Gesellschaft f&#xfc;r Liquordiagnostik und Klinische Neurochemie (Hrsg.), Leitlinien f&#xfc;r Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien. abgerufen am 07 May 2020.</Citation></Reference><Reference><Citation>Petereit HF, Sindern E, Wick M. [CSF diagnostics. Guidelines and catalogue of methods of the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry] Heidelberg: Springer; 2007.</Citation></Reference><Reference><Citation>Tumani H, Petereit HF, Gerritzen A, Gross CC, Huss A, Isenmann S, Jesse S, Khalil M, Lewczuk P, Lewerenz J, et al. S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version) Neurol Res Pract. 2020;2:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7650145</ArticleId><ArticleId IdType="pubmed">33324914</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073070</ArticleId><ArticleId IdType="pubmed">8057110</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Cerebrospinal fluid&#x2013;physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762655</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762657</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Flow rate of cerebrospinal fluid (CSF)&#x2013;a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122:189&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzior H, Fiebich BL, Yousif NM, Saliba SW, Ziegler C, Nickel K, Maier SJ, Suss P, Runge K, Matysik M, et al. Increased IL-8 concentrations in the cerebrospinal fluid of patients with unipolar depression. Compr Psychiatry. 2020;102:152196.</Citation><ArticleIdList><ArticleId IdType="pubmed">32927367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Tao X, Xu M. Value of cerebrospinal fluid IL-8 and IFN-&#x3b3; level in early diagnosis of tuberculous meningitis and evaluation of prognosis. Acta Medica Mediterranea. 2020;36:2875.</Citation></Reference><Reference><Citation>Kaminska J, Lyson T, Chrzanowski R, Sawicki K, Milewska AJ, Tylicka M, Zinczuk J, Matowicka-Karna J, Dymicka-Piekarska V, Mariak Z, Koper-Lenkiewicz OM. Ratio of IL-8 in CSF versus Serum Is Elevated in Patients. J Clin Med. 2020;9:1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356854</ArticleId><ArticleId IdType="pubmed">32517149</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, Fritzinger M, Horn P, Vajkoczy P, Kreisel S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70:534&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737308</ArticleId><ArticleId IdType="pubmed">11254783</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Ruocco HH, Brandao CO, Costallat LTL, Silva L, Cendes F, Appenzeller S. Interferon-gamma Is Associated with Cerebral Atrophy in Systemic Lupus Erythematosus. NeuroImmunoModulation. 2017;24:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">28848179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand. 2001;104:288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">11696023</ArticleId></ArticleIdList></Reference><Reference><Citation>Glimaker M, Kragsbjerg P, Forsgren M, Olcen P. Tumor necrosis factor-alpha (TNF alpha) in cerebrospinal fluid from patients with meningitis of different etiologies: high levels of TNF alpha indicate bacterial meningitis. J Infect Dis. 1993;167:882&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">8015728</ArticleId></ArticleIdList></Reference><Reference><Citation>Starhof C, Winge K, Heegaard NHH, Skogstrand K, Friis S, Hejl A. Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. J Neuroinflammation. 2018;15:305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215346</ArticleId><ArticleId IdType="pubmed">30390673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildemann B, Oschmann P, Reiber H. Laboratory diagnosis in neurology. Stuttgart: Thieme; 2011.</Citation></Reference><Reference><Citation>Wurster U, Stachan R, Windhagen A, Petereit HF, Leweke FM. Reference values for standard cerebrospinal fluid examinations in multiple sclerosis. Results from 99 healthy volunteers. Mult Scler. 2006;12:P248.</Citation></Reference><Reference><Citation>Schwenkenbecher P, Janssen T, Wurster U, Konen FF, Neyazi A, Ahlbrecht J, Puppe W, Bonig L, Suhs KW, Stangel M, et al. The influence of blood contamination on cerebrospinal fluid diagnostics. Front Neurol. 2019;10:584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582628</ArticleId><ArticleId IdType="pubmed">31249547</ArticleId></ArticleIdList></Reference><Reference><Citation>Abela I, Pasin C, Schwarzm&#xfc;ller M, Epp S, Sickmann M, Schanz M, Rusert P, Weber J, Schmutz S, Audig&#xe9; A, et al. Multifactorial SARS-CoV-2 seroprofiling dissects interdependencies with human coronaviruses and predicts neutralization activity. Nat Commun. 2021;12:6703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602384</ArticleId><ArticleId IdType="pubmed">34795285</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, Wildemann B. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">28005176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378:840&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">29490181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermetter C, Fazekas F, Hochmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. Front Neurol. 2018;9:706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6135049</ArticleId><ArticleId IdType="pubmed">30233481</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291:52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20117794</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028894</ArticleId><ArticleId IdType="pubmed">24118483</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H, Zeman D, Kusnierova P, Mundwiler E, Bernasconi L. Diagnostic relevance of free light chains in cerebrospinal fluid&#x2014;The hyperbolic reference range for reliable data interpretation in quotient diagrams. Clin Chim Acta. 2019;497:153&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">31351929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenkenbecher P, Konen FF, Wurster U, Witte T, Gingele S, Suhs KW, Stangel M, Skripuletz T. Reiber's diagram for kappa free light chains: the new standard for assessing intrathecal synthesis? Diagnostics (Basel) 2019;9:194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963502</ArticleId><ArticleId IdType="pubmed">31744096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kestner M, Rosler AE, Baumg&#xe4;rtner M, Lindner A, Orth M. CSF interleukin 6&#x2014;a useful biomarker of meningitis in adults?/Liquor Interleukin 6&#x2014;a ein sinnvoller Biomarker f&#xfc;r die Meningitis beim Erwachsenen. J Lab Med. 2011;35:107&#x2013;113.</Citation></Reference><Reference><Citation>Espindola OM, Siqueira M, Soares CN, Lima M, Leite A, Araujo AQC, Brandao CO, Silva MTT. Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid. Int J Infect Dis. 2020;96:567&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271861</ArticleId><ArticleId IdType="pubmed">32505878</ArticleId></ArticleIdList></Reference><Reference><Citation>Destras G, Bal A, Escuret V, Morfin F, Lina B, Josset L, Group CO-DHS Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic. Lancet Microbe. 2020;1:e149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289579</ArticleId><ArticleId IdType="pubmed">32835345</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis. 2002;34:1154&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">11915008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ, Kaplan SL, Scheld WM, Whitley RJ, Infectious Diseases Society of A The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47:303&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">18582201</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner I, Schmutzhard E, Sellner J, Chaudhuri A, Kennedy PG, European Federation of Neurological S, European Neurologic S EFNS-ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system. Eur J Neurol. 2012;19:1278&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">22882231</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YH, Jiang D, Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immun. 2020;87:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202824</ArticleId><ArticleId IdType="pubmed">32387508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Stich O, Rasiah C, Voltz R, Rauer S. Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci. 2008;268:65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18096187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, Rauer S. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients. J Neuroimmunol. 2010;229:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">20813415</ArticleId></ArticleIdList></Reference><Reference><Citation>Stich O, Graus F, Rasiah C, Rauer S. Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol. 2003;141:165&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12965268</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig. 1992;70:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1318123</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen JL, Sindic CJ. Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler. 1998;4:22&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9532588</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Eichhorn P, Wildemann B, Wick M. Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS. 2012;9:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487855</ArticleId><ArticleId IdType="pubmed">22849518</ArticleId></ArticleIdList></Reference><Reference><Citation>Stich O, Kluge J, Speck J, Rauer S. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients. Acta Neurol Scand. 2015;131:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">25402869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindic CJ, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol. 1994;54:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523446</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht I, Weissbrich B, Braun J, Toyka KV, Weishaupt A, Buttmann M. Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. PLoS ONE. 2012;7:e40431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392215</ArticleId><ArticleId IdType="pubmed">22792316</ArticleId></ArticleIdList></Reference><Reference><Citation>Stich O, Kluge J, Speck J, Rauer S. Detection of virus-specific (measles, rubella, zoster) oligoclonal IgG-bands in CSF from multiple sclerosis patients without oligoclonal bands of total IgG. Mult Scler. 2009;15:S86.</Citation></Reference><Reference><Citation>Kreye J, Reincke SM, Pruss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat Rev Immunol. 2020;20:645&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537977</ArticleId><ArticleId IdType="pubmed">33024283</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758411</ArticleId><ArticleId IdType="pubmed">33361764</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Hussain B, Chang J. Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms. CNS Neurosci Ther. 2021;27:36&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804893</ArticleId><ArticleId IdType="pubmed">33381913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Zuo Y, Gandhi AA, Sule G, Yalavarthi S, Gockman K, Madison JA, Wang J, Zuo M, Shi Y, et al. Endothelial cell-activating antibodies in COVID-19. MedRxiv. 2021;109:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082472</ArticleId><ArticleId IdType="pubmed">35174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YH, Huang YH, Chuang YH, Peng CM, Wang LC, Lin YT, Chiang BL. Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Virol. 2005;77:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166512</ArticleId><ArticleId IdType="pubmed">16032747</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, Reilly N, Ottaviani G, Elghetany MT, Trujillo DO, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48:107233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204762</ArticleId><ArticleId IdType="pubmed">32434133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacout C, Rogez J, Orvain C, Nicot C, Rony L, Julien H, Urbanski G. A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19. Rheumatology (Oxford) 2021;60:e19&#x2013;e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543632</ArticleId><ArticleId IdType="pubmed">32940700</ArticleId></ArticleIdList></Reference><Reference><Citation>Case R, Ramaniuk A, Martin P, Simpson PJ, Harden C, Ataya A. Systemic capillary leak syndrome secondary to coronavirus disease 2019. Chest. 2020;158:e267&#x2013;e268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332444</ArticleId><ArticleId IdType="pubmed">32622823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sussmuth SD, Sperfeld AD, Ludolph AC, Tumani H. Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis. Neurochem Res. 2010;35:1071&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">20333464</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, James LC, Lancaster MA. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell. 2020;27:951&#x2013;961.e955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CL, Staples H, Gazi M, Carrion R, Hsieh J. SARS-CoV-2 targets glial cells in human cortical organoids. Stem Cell Reports. 2021;16:1156&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111796</ArticleId><ArticleId IdType="pubmed">33979600</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob F, Pather SR, Huang WK, Zhang F, Wong SZH, Zhou H, Cubitt B, Fan W, Chen CZ, Xu M, et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell. 2020;27:937&#x2013;950.e939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman RA, Sligar K, Hake RB. Effects of leukocytes on brain metabolism in granulocytic brain edema. Ann Neurol. 1977;2:89&#x2013;94.</Citation></Reference><Reference><Citation>Jordan GW, Statland B, Halsted C. CSF lactate in diseases of the CNS. Arch Intern Med. 1983;143:85&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolmel HW, von Maravic M. Correlation of lactic acid level, cell count and cytology in cerebrospinal fluid of patients with bacterial and non-bacterial meningitis. Acta Neurol Scand. 1988;78:6&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3176884</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen NE, Gyring J, Hansen AJ, Laursen H, Siesjo BK. Brain acidosis in experimental pneumococcal meningitis. J Cereb Blood Flow Metab. 1989;9:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">2497112</ArticleId></ArticleIdList></Reference><Reference><Citation>Simchowitz L, Textor JA. Lactic acid secretion by human neutrophils. Evidence for an H+ + lactate- cotransport system. J Gen Physiol. 1992;100:341&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2229137</ArticleId><ArticleId IdType="pubmed">1402785</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz W, Mukerji S. Lactate production and release in cultured astrocytes. Neurosci Lett. 1988;86:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">3380321</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz W, Mukerji S. Lactate release from cultured astrocytes and neurons: a comparison. Glia. 1988;1:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">2976396</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner JB, Plum F. Independence of blood and cerebrospinal fluid lactate. Arch Neurol. 1967;16:492&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">6022530</ArticleId></ArticleIdList></Reference><Reference><Citation>Plum F, Posner JB. Blood and cerebrospinal fluid lactate during hyperventilation. Am J Physiol. 1967;212:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">6024452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebant B, Miret N, Bouwyn JP, Delafosse E, Lefaucheur R. Absence of pleocytosis in cerebrospinal fluid does not exclude herpes simplex virus encephalitis in elderly adults. J Am Geriatr Soc. 2015;63:1278&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">26096420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sili U, Kaya A, Mert A, Group HSVES Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients. J Clin Virol. 2014;60:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">24768322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932838</ArticleId><ArticleId IdType="pubmed">29724224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283476</ArticleId><ArticleId IdType="pubmed">22260418</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O. Immunopathogenesis of neuromyelitis optica. Adv Immunol. 2014;121:213&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">24388217</ArticleId></ArticleIdList></Reference><Reference><Citation>Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol. 2019;10:804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670288</ArticleId><ArticleId IdType="pubmed">31404257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci. 2008;268:74&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">18068189</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Maldonado Slootjes S, Sellimi A, Bronchain M, Hanseeuw B, Belkhir L, Yombi JC, De Greef J, Pothen L, Yildiz H, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol. 2021;268:751&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, Steinbrenner M, Angermair S, Treskatsch S, Zickler D, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Zhou Y, Cai L, Wang L, Han J, Yang X, Chen J, Chen J, Ma C, Shen L. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br J Dermatol. 2020;183:1145&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436688</ArticleId><ArticleId IdType="pubmed">32790074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartari F, Spadotto A, Zengarini C, Zanoni R, Guglielmo A, Adorno A, Valzania C, Pileri A. Herpes zoster in COVID-19-positive patients. Int J Dermatol. 2020;59:1028&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307064</ArticleId><ArticleId IdType="pubmed">32530063</ArticleId></ArticleIdList></Reference><Reference><Citation>Saati A, Al-Husayni F, Malibari AA, Bogari AA, Alharbi M. Herpes zoster co-infection in an immunocompetent patient with COVID-19. Cureus. 2020;12:e8998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358933</ArticleId><ArticleId IdType="pubmed">32670724</ArticleId></ArticleIdList></Reference><Reference><Citation>Nofal A, Fawzy MM, El Sharaf Deen SM, El-Hawary EE. Herpes zoster ophthalmicus in COVID-19 patients. Int J Dermatol. 2020;59:1545&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675560</ArticleId><ArticleId IdType="pubmed">33040343</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Undavia A, Choudry R, Zhang Y, Prabhu AM. COVID-19 associated with concomitant varicella zoster viral encephalitis. Neurol Clin Pract. 2021;11:e219&#x2013;e221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032442</ArticleId><ArticleId IdType="pubmed">33842100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>